Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PRT3789 |
Trade Name | |
Synonyms | PRT-3789|PRT 3789 |
Drug Descriptions |
PRT3789 is a SMARCA2 degrader, which potentially decreases proliferation of tumor cells with SMARCA4 loss and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3263). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Docetaxel + PRT3789 | Docetaxel PRT3789 | 0 | 1 |
Pembrolizumab + PRT3789 | PRT3789 Pembrolizumab | 0 | 0 |
PRT3789 | PRT3789 | 3 | 1 |